Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 11Nivolumab 6Cetuximab 5Gemcitabine 4Filgrastim 4Cisplatin 4Carboplatin 4tislelizumab 3Radiosurgery 3Ipilimumab 3Injections 3Fluorouracil 3Docetaxel 3Cyclophosphamide 3Bortezomib 3toripalimab 2spartalizumab 2poly ICLC 2pazopanib 2entrectinib 2durvalumab 2cemiplimab 2belinostat 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Riluzole 2Peripheral Blood Stem Cell Transplantation 2Oncolytic Virotherapy 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Medicare Part B × Head & Neck × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡